ForeSENTIA: Breast / Gynecological
The ForeSENTIA Breast/Gynaecological panel tests for single nucleotide variants, insertions, deletions, copy number alterations, and rearrangements in 48 genes which are commonly found in gynaecological cancers such as breast, ovarian, and others. Different risk factors can contribute to the development of gynecological cancers such as inheritance, increase in age, and environmental factors. Identifying the genetic alterations that can contribute to cancer progression can help in therapy selection and re-evaluation. There are numerous FDA/EMA-approved therapies for gynecological cancers depending on the type of cancer and the mutations identified.
Microsatellite instability (MSI) immunotherapy biomarker can optionally be in this panel. The FDA-approved immunotherapy drug pembrolizumab is also available for treating patients with MSI-high status. Pembrolizumab has also been approved by the EMA for endometrial cancer.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?


Certified laboratories

